PRESTIGE CONSUMER HEALTHCARE INC.
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) has a dated report snapshot, but its current priced-in claim is temporarily suppressed because the live engine record is unavailable or has changed.
• Prestige owns a portfolio of niche over-the-counter consumer health brands at a 28% operating margin, the economics of category leaders that need little reinvestment and throw off steady cash. • The cash funds an acquisition machine: the company is buying the Breathe Right nasal-strip brand and Australia's LaCorium skin-care business, financed with new term debt that lifts leverage before cash flow brings it back down. • The structural worry is organic decline, full-year revenue fell about 4%,
Is PBH overvalued? See what's priced in →
341 institutional managers reported holding PBH in 13F filings for the quarter ended 2026-03-31. 47 opened new positions that quarter. Held by BlackRock, Vanguard Group, Dimensional Fund Advisors, among others. On the short side, 2.9M shares were sold short as of the 2026-06-15 count, about 6% of shares outstanding (4.6 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
PBH has cut its share count 4.5% over the past five years, spending $305.65M on repurchases. It pays no dividend. Cash returned over the past three years: $219.59M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at PBH over the trailing three years. Absence is a fact about the company, not a signal. 13 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
PBH's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-04 | +2.1% | -13.2% |
| 2023-11-03 | +0.1% | -1.2% |
| 2024-02-09 | +9.2% | -0.6% |
| 2024-05-16 | -5.7% | +10.1% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
PBH's latest 8-K filings: 2026-07-15 (items 1.01, 2.03, 9.01); 2026-07-06 (items 1.01, 2.03, 7.01, 9.01); 2026-06-16 (items 1.01, 2.01, 2.03, 8.01, 9.01); 2026-05-13 (items 1.01, 2.02, 7.01, 9.01); 2026-03-20 (items 1.01, 7.01, 8.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 28, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.